DAFTAR PUSTAKA 1. Sofian A.,Kanker Endometrium. In: Buku Acuan Nasional Onkologi Ginekologi. Yayasan Bina Pustaka Sarwono Prawirohardjo, Jakarta, 2006 : 456-467 2. Sankaranarayanan R., Worldwide Burden of Gynecological Cancer. Springer Science. 2010: 804-814 3. Siregar M. Angka Kejadian dan Karakteristik Penderita Kanker Ginekologi di RSUP H. Adam Malik dan RSUD dr. Pirngadi Medan. Tesis pada Bagian Obstetri dan Ginekologi FK USU/ RSup H. Adam Malik Medan. Mei 2002. 4. Sahil MF., Limfadenektomi pada Karsinoma Endometrium Stadium I Perlu atau Tidak?, Majalah Kedokteran Nusantara,2,38 (2005):189-194 5. Andrijono. Perjalanan Penyakit dan Deteksi Dini. In: Kanker Serviks. Divisi Onkologi Departemen Obstetri-Ginekologi. Fakultas Kedokteran Universitas Indonesia, 2009:1-19 6. Zaloudek C. Adenocarcinoma of the Cervix. Department of Pathology. University of California. 2010:1-16 7. Zaino RJ. The fruit of our labors: Distinguishing endometrial from endocervical adenocarcinoma. Int J Gynaecol Pathol 2002;21:1-3 8. McCluggage WG. A panel of immunohistochemical stains, including carcinoembrionic antigen, vimentin and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas. Int J Gynecol Pathol 2002;21:11-5 62
9. Sofian A. The role of Vimentin Immunohistochemistry Examination as Tissue Origin Marker of Endometrial Cancer. Unversity of Indonesia. Maj Kedokt Indo 2006;56:46-50 10. Jones M.,Endometrial Carcinoma. In: Novaks Text Book of Gynecology. Eleventh Edition, Williams & Wilkins Baltimore, 1988: 728-757 11. Ghada E. ProExC is a novel marker for distinguishing between primary endometrial and endocervical adenocarcinomas. Journal of the Egyptian National Cancer Institute 2013;25:87-93 12. Chandrasoma P. Ringkasan Patologi Anatomi. Penerbit Buku Kedokteran EGC. Jakarta.2006:240-254 13. Lurain JR. Uterine cancer. In: Berek JS. Berek & Novak s Gynecology, 14 th ed. Philadelphia: Lippincott Williams & Wilkins; 2007, p.1343-82 14. Schorge J. Endometrial Cancer. Dalam: Cunningham FG. Williams Gynecology. USA: McGraw-Hill. 2008 15. Djordjevic B. Selected Topics In The Molecular Pathology of Endometrial Carcinoma. Surgical Pathology. 2011:131-147 16. Bansal N. The Molecular Biology of Endometrial Cancers and the Implications for Pathogenesis, Classification, and Targeted Therapies. Cancer Control,2009;16:8-14 17. Banno K. Candidate Biomarkers for Genetic and Clinicopathological Diagnosis of Endometrial Cancer. International Journal of Molecular Sciences. 2013:12123-12137 63
18. Platz CE, Benda JA. Female genital tract cancer. Cancer 2000; 75:Suppl: 270-94. 19. Hacker NF. Uterine cancer. In: Berek JS, Hacker NF. Practical Gynecologic Oncology, 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2005, p.397-435. 20. Levine D.,The Corpus: Epithelial Tumors. In: Handbook for Principles and Practice of Gynecologic Oncology. Lippincott Williams & Wilkins,2010:159-190 21. Levy T, Golan A, Menczer J. Endometrial endometrioid carcinoma: A glimpse at the natural course. American Journal of Obstetrics and Gynecology, 2006, vol.195, p.454 457 22. Soekimin H. Adenocarcinoma Endometrium. Patologi Anatomi. Universitas Sumatera Utara. e-usu Repository 2005. 23. Andrijono. Panduan Pelayanan Medik Ginekologi Onkologi. Perkumpulan Obstetri Ginekologi Indonesia. Himpunan Onkologi Ginekologi Indonesia. Juni 2007:13-27 24. Cechini S. Sensitivity of the screening Program for Cervical cancer in the Florence District. Gynecol Oncol. 1999,33:182-4 25. Reid M. Immunophenotypic diversity of endometrial adeno carcinomas: implications for differential diagnosis. Mod Pathol. 2006 Aug;19(8):1091-100 26. Satelli A. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell. Mol. Life Sci.2011;68:3033-3046 64
27. Fuchs E. Intermediate filaments: structure, dynamics, function, and disease. Annu Rev Biochem. 1994. 63: pp. 345 82. 28. Chang L, Shav-Tal Y. Assembling an intermediate filament network by dynamic cotranslation. J Cell Biol 2006.172 (5): 747 58. 29. Katsumoto T. The role of the vimentin intermediate filaments in rat 3Y1 cells elucidated by immunoelectron microscopy and computergraphic reconstruction. Biol Cell 2000.68 (2): pp. 139 46. 30. Goldman R. The function of intermediate filaments in cell shape and cytoskeletal integrity. J. Cell Biol. 1996.134 (4): 971 83. 31. Franke W. Rearrangement of the Vimentin Cytoskeleton during Adipose Conversion: Formation of an Intermediate Filament Cage around Lipid Globule. Cell. 1987(49):131-141 32. Lieber J. Disruption of the vimentin intermediate filament system during adipose conversion of 3T3-L1 cells inhibits lipid droplet accumulation. Journal of Cell Science. 1996:3047-3058 33. Green H. An established preadipose cell line and its differentiation in culture. Factors affecting the adipose conversion. Cell(1):19-27 34. Dabss DJ. Intermediate filaments in endometrial and endocervical carcinomas. The diagnostic utility of Vimentin patterns. Am J Surg Pathol 1996;10:568-76 35. Alfred C. Assessment of Prognostic and Predictive Factors in Breast Cancer by Immunohistochemistry. Connection 9;2006:4-5 65
36. Qureshi A. Allred scoring for ER reporting and it s impact in clearly distinguishing ER negative from ER positive breast cancers. Journal Pathology Medical Association.2010 (60):350-353 37. Dako.ER/PR PharmDx Interpretation Manual.Nov 2007;28252: 1-23 38. Kim EH. Comparison of estrogen receptor, progesterone receptor and calponin expression in gonadotrophin-releasing hormone agonist-sensitive. Obstet Gynecol Sci. 2014;57:144-150 39. Coppola D. Prognostic Significance of p53, bcl-2, Vimentin, and S100 Protein-Positive Langerhans Cells in endometrial cancer. Human Pathology. 1998;29:455-462 40. Soslow A. Uterine Cancer: Pathology In: Uterine Cancer. Current Clinical Oncology. Humana Press Springer Science. 2009:51-78 41. Kamoi S. Immunohistochemical staining in the distinction between primary endometrial and endocervical adenocarcinoma; another viewpoint. Int J Gynecol Pathol 2002;21:217-23 42. Castrillon DH. Distinction between endometrial and endocervical adenocarcinoma: an immunohistochemical study. Int. J Gynecol Pathol. 2002;1:4-10 43. Sastroasmoro S. Dasar-dasar metodologi penelitian klinis. Edisi Keempat. Sagung Seto. 2013. 44. Wiknjosastro H. Tumor Ganas Alat Genital In: Ilmu Kandungan. Yayasan Bina Pustaka Sarwono Prawirohardjo. 2008:380-394 66
45. Chiang S. Updates in Diagnostic Immunohistochemistry in Endometrial Cancer. Department of Pathology. Memorial Sloan Kettering Cancer Center.2010 46. Alwi H. Kamus Besar Bahasa Indonesia. Jakarta: Balai Pustaka. 2007 47. Physical activity and Health Adolescent In: Centers for Disease Control and Prevention. 2009. 48. Robbins C. Pathologic Basis of Disease. Roldusandy Published. 2005. 102-128 49. Howlader, N., et al. SEER Cancer Statistics Review, 1975-2008. 2011 [cited 2011; based on November 2010 SEER data submission]. 50. Noviardi. Karakteristik dan Kelangsungan Hidup Penderita Karsinoma Korpus Uteri yang Dirawat di RS Dr. Pirngadi Medan Tahun 1981-1990. Tesis pada Bagian Obstetri dan Ginekologi FK USU/ RS Dr. Pirngadi Medan. Juni 1994. 51. Wee C. BMI and cervical cancer screening among white, African- American, and Hispanic women in the United States.Obes Res.2005:1275-80. 52. Green J. Risk Factors for Adenocarcinoma and Squamos Cell Carcinoma of the Cervix in Women Aged 20-44 years: the UK National Case-Control Study of Cervical Cancer. British Journal of Cancer. 2003;2078-86. 67
53. Cirisano F. Epidemiologic and Surgicopathologic Findings of Papillary Serous and Clear Cell Endometrial Cancers When Compared to Endometrioid Carcinoma. Gynecol Oncol. 1999;385-394. 68